Navigation Links
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
Date:11/6/2008

- Third quarter net loss narrows on higher revenue due to Roche milestone -

BRISBANE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2008. InterMune reported a net loss for the third quarter of 2008 of $12.5 million, or $0.32 per share, compared with a net loss of $23.1 million, or $0.66 per share, in the third quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Third quarter and recent events have highlighted our significant progress on pirfenidone and ITMN-191. On October 16, Shionogi's Japanese NDA for pirfenidone was approved, making pirfenidone the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We reported exceptional patient retention in our Phase 3 CAPACITY program for pirfenidone in IPF and we set the expectation for announcement of top-line results from CAPACITY in January or February of 2009. With ITMN-191, we remain committed to announcing top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) during this quarter."

Results for Third Quarter 2008

InterMune reported total revenue in the third quarter of 2008 of $23.3 million, compared with total revenue of $11.4 million in the third quarter of 2007. Total revenue in the third quarter of 2008 primarily consisted of revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191 (R7227), which totaled $15.8 million in the third quarter of 2008, compared with $0.8 million in the same quarter of 2007. Third quarter 2008 collaborati
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Miami, FL (PRWEB) May 20, 2013 Researchers ... information in the connection between lower back pain, and the ... of P.acnes in the system the bacteria seek out oxygen ... is incurred in the spinal column, P.acnes has the ability ... pain. , Fernando Perez, a spokesman for “ The ...
(Date:5/20/2013)... Recognizing exciting and innovative scientific ... its 2013 Class of Young Professors. Over ... this outstanding international group with more than $824,000 ... to meet global challenges.     , The DuPont Young ... and untenured research faculty working in areas of ...
(Date:5/20/2013)... May 20, 2013 On 25-28 July, ... – in Paris - the beautiful city of lights. ... "Personalized Medicine is revolutionizing the medical world. Understanding and ... is the hallmark of this transformation. Much of the ... from the epidemiologic studies of large cohorts that do ...
(Date:5/20/2013)... Kitware, a leader in data visualization, today ... exploration of hospital costs across the United States ... recent release of “Medicare Provider Charge Data,” a dataset ... from the Centers for Medicare & Medicaid Services. , ... hospitals across the country has sparked considerable controversy; however, ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2Kitware Enables Interactive Exploration of CMS Medicare Data 2
... , , ... today announced that it has been awarded two Phase I ... the National Institute of Allergy and Infectious Diseases (NIAID) of ... be used to perform additional preclinical toxicology and pharmacology studies ...
... , , , ... ), the leading global provider of risk management services, ... human capital consulting , today issued the findings of its 2009 ... biotechnology , pharmaceutical and medical ...
... YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain, ... Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... development company that identifies and advances a diverse portfolio ... today reported that nimotuzumab has been approved for marketing ...
Cached Biology Technology:Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome 2Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 2Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 3Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 4Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map 5YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 2YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 3YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO 4
(Date:5/19/2013)... study reports that white men and women of European ... valgus) and lesser toe deformities, including hammer or claw ... estimate the heritability of foot disorders in humansappear in ... by Wiley on behalf of the American College of ... many as 60% of older adults have foot disorders ...
(Date:5/19/2013)... a strain of electricity-producing bacteria that can grow using ... dioxide as its sole source of carbon. Researchers ... at the 113th General Meeting of the American Society ... current production solely on hydrogen," says Amit Kumar, a ... are part of the Lovley Lab Group at the ...
(Date:5/19/2013)... engineered a strain of photosynthetic cyanobacteria to grow without ... today at the 113th General Meeting of the American ... synthetic biology approaches to probe and rewire photoautotrophic (exclusively ... cyanobacterial metabolism for the ability to grow without light ... study. He is part of Shota Atsumi,s lab ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2
... edition of the Oxford English Dictionary boasts 22,000 pages of ... suggests the reference manual is meticulously organized to be as ... our brains make sense of and categorize the countless words ... of as a frustratingly tangled web of words where the ...
... by Yale scientists shows that males and females have essentially ... a recent report in Cell designed to identify factors that ... showed that a courting song and dance routine that only ... wiggled to make a humming song can also be ...
... of Southern California School of Dentistry researchers says it ... some people taking drugs that treat osteoporosis. Microbial ... are causing jaw tissue infections in patients taking bisphosphonate ... professor at the USC School of Dentistry. ...
Cached Biology News:Decoding the dictionary: Study suggests lexicon evolved to fit in the brain 2Decoding the dictionary: Study suggests lexicon evolved to fit in the brain 3It's a unisex brain with specific signals that trigger 'male' behavior 2USC School of Dentistry researchers uncover link between osteoporosis drugs and jaw infection 2
... Attoglow Western Blot Analysis Kit is ... kit developed by Biochain. It detects ... g) or yoctomole (10 -24 ... three parts: Millennium Enhancer, protein interaction ...
Request Info...
Cultrex 3D Culture Matrix Rat Collagen I....
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
Biology Products: